Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
6.02
-0.83 (-12.12%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Forte Biosciences Stock Forecast
FBRX's stock price has decreased by -66.56% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Forte Biosciences stock have an average target of 80.5, with a low estimate of 61 and a high estimate of 100. The average target predicts an increase of 1,237.21% from the current stock price of 6.02.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Forte Biosciences stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $64 → $61 | Strong Buy | Maintains | $64 → $61 | +913.29% | Apr 1, 2025 |
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Jan 21, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $64 | Strong Buy | Maintains | $64 | +963.12% | Dec 4, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $3 → $64 | Strong Buy | Maintains | $3 → $64 | +963.12% | Nov 15, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $75 | Strong Buy | Maintains | $75 | +1,145.85% | Aug 19, 2024 |
Financial Forecast
Revenue This Year
n/a
from 66.18M
Revenue Next Year
n/a
EPS This Year
-3.67
from -12.17
EPS Next Year
-2.30
from -3.67
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.36 | -1.71 | -1.33 | ||
| Avg | -3.67 | -2.30 | -2.57 | ||
| Low | -4.17 | -3.02 | -3.68 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.